Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 127 participants.

Also called NCT02721888

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 127 participants (enrolled count) (from the registry)
Sponsor
Centre Hospitalier Universitaire Dijon (from the registry)
Registry
  • NCT NCT02721888
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Countries
France (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02721888. Allocation not applicable; no masking; primary purpose treatment. Start 2012-07-10 (actual); primary completion 2019-10-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism
Acronym
LIRA-NAFLD/LIP
Intervention (Drug)
Liraglutide
Intervention (Drug)
MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
Intervention (Biological)
Blood sample
Intervention (Other)
Kinetic substudy (10 patients)
Lead sponsor
Centre Hospitalier Universitaire Dijon (class: other)

Record details

Record id
cardio:ct-nct02721888
Content hash
5be24d74b5d2758a46dba7ae1af7e5002fd4135f81960c3e7e200d77a4c580cf